phrma logo

PhRMA

PhRMA Sites

Login

Explore Member-Only Resources

Access exclusive advocacy, policy, and research materials through the member site.

Login now

About

About

Our Agenda

Our Agenda

Policy Issues

We believe that patients should have access to innovative medicines.

Learn More

Innovation Ecosystem

Intellectual Property

Research & Development

Future of Medicine

Government Price Setting

International

Innovation Ecosystem

Patient Access & Affordability

PBMs & Middlemen

Hospitals and 340B

Insurance Coverage

Cost of Medicines

Medicare & Medicaid

Patient Access & Affordability

Resources

Our mission is to conduct effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies.

Learn More

Resources

Resources

Newsroom

Newsroom

Blog

Blog

America's Medicines

PhRMA Foundation

PhRMA Foundation Logo

Voters for Cures

VotersForCures.org Logo

Working for Cures

workersforcures.org logo

This is Innovation

Innovation.org logo

View More

Search in PhRMA

Find resources, news, and articles related to policy issues and scientific innovation.

What are you looking for?

Most Recent

Policy Paper

Press

Blog

Report

Fact Sheet

Event

Resource

Pages

Leader

Author

Comment

not used title

not used title

PhRMA president and CEO Stephen J. Ubl joined Fox Business’ Maria Bartiromo on “Mornings with Maria” today to discuss bold steps the biopharmaceutical industry has taken in the last few months as part of its commitment to advance a multifaceted solution to address the opioid crisis. Most recently, PhRMA announced its support for policies limiting the supply of opioids to seven days for acute pain treatment.

PhRMA has also been working closely with the President’s Commission on Combating Drug Addiction and the Opioid Crisis, the National Institutes of Health (NIH) and the Food and Drug Administration to develop a public-private partnership that will accelerate the development of non-opioid, non-addictive pain medicines and medication-assisted treatments for long-term addiction recovery. The public-private partnership would allow increased information sharing and collaboration between government and industry to speed the drug development process.

Holly Campbell

Holly Campbell is former deputy vice president of public affairs at PhRMA focusing on the cost and value of medicines.

Holly Campbell

Author Twitter

Author LinkedIn

Mass compounding puts patients at risk

July 16, 2026

CMS’ MFN proposals won’t help seniors despite lofty promises

April 9, 2026

Voters voice concerns on government price controls

April 7, 2026

Advancing patient care: A look at new medicines approved in 2025

January 30, 2026

VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria

FDA

Patients

Prescription Drug Safety

VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria

October 12, 2017

VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria

Stay current on policy making

Sign up for email updates and follow us on social. 

About

Our Agenda

Policy Issues

Resources

Blog

Contact Us

Privacy Policy

Terms of Service

Facebook

Facebook

X

Twitter X

LinkedIn

LinkedIn

Instagram

instagram logo

America's Medicines

PhRMA Foundation

Voters for Cures

Working for Cures

Innovation.org

Please type your email

Success!

You've been added to the list